And Then There Were Three: J&J/Cordis Exits Drug-Eluting Stent Market
This article was originally published in The Gray Sheet
The first company to enter the drug-eluting stent market will now be the first to depart.
You may also be interested in...
The company is initially targeting very small vessels in a new pivotal study for its Resolute Onyx zotarolimus-eluting stent. Medtronic is separately launching a study of its novel "drug-filled" stent platform.
The $1.99 billion Cordis acquisition is a major step in Cardinal's strategy to build its offerings of devices with a high physician preference but for which there is limited clinical differentiation and inefficient supply chains.
NICE changes name, leader, and expands mission to social care. Cordis wins Cypher patent case on appeal. More news in brief.